Logo image of NXGL

NEXGEL INC (NXGL) Stock Fundamental Analysis

NASDAQ:NXGL - US65344E1073 - Common Stock

2.3 USD
-0.05 (-2.13%)
Last: 9/3/2025, 8:00:02 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to NXGL. NXGL was compared to 190 industry peers in the Health Care Equipment & Supplies industry. NXGL may be in some trouble as it scores bad on both profitability and health. NXGL is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NXGL has reported negative net income.
In the past year NXGL has reported a negative cash flow from operations.
NXGL had negative earnings in each of the past 5 years.
NXGL had a negative operating cash flow in each of the past 5 years.
NXGL Yearly Net Income VS EBIT VS OCF VS FCFNXGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -1M -2M -3M -4M

1.2 Ratios

With a Return On Assets value of -30.07%, NXGL perfoms like the industry average, outperforming 43.16% of the companies in the same industry.
Looking at the Return On Equity, with a value of -62.51%, NXGL is in line with its industry, outperforming 47.37% of the companies in the same industry.
Industry RankSector Rank
ROA -30.07%
ROE -62.51%
ROIC N/A
ROA(3y)-35.81%
ROA(5y)-46.56%
ROE(3y)-62.13%
ROE(5y)-690.12%
ROIC(3y)N/A
ROIC(5y)N/A
NXGL Yearly ROA, ROE, ROICNXGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

1.3 Margins

NXGL has a worse Gross Margin (38.62%) than 69.47% of its industry peers.
In the last couple of years the Gross Margin of NXGL has grown nicely.
NXGL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 38.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y266%
GM growth 5YN/A
NXGL Yearly Profit, Operating, Gross MarginsNXGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

1

2. Health

2.1 Basic Checks

NXGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
NXGL has more shares outstanding than it did 1 year ago.
NXGL has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, NXGL has a worse debt to assets ratio.
NXGL Yearly Shares OutstandingNXGL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
NXGL Yearly Total Debt VS Total AssetsNXGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -0.15, we must say that NXGL is in the distress zone and has some risk of bankruptcy.
NXGL has a Altman-Z score (-0.15) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.17 indicates that NXGL is not too dependend on debt financing.
NXGL has a Debt to Equity ratio of 0.17. This is comparable to the rest of the industry: NXGL outperforms 56.84% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Altman-Z -0.15
ROIC/WACCN/A
WACC8.63%
NXGL Yearly LT Debt VS Equity VS FCFNXGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 5M 10M

2.3 Liquidity

A Current Ratio of 1.74 indicates that NXGL should not have too much problems paying its short term obligations.
NXGL's Current ratio of 1.74 is on the low side compared to the rest of the industry. NXGL is outperformed by 70.00% of its industry peers.
NXGL has a Quick Ratio of 1.74. This is a bad value and indicates that NXGL is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of NXGL (0.98) is worse than 76.32% of its industry peers.
Industry RankSector Rank
Current Ratio 1.74
Quick Ratio 0.98
NXGL Yearly Current Assets VS Current LiabilitesNXGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

7

3. Growth

3.1 Past

NXGL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.20%, which is quite impressive.
The Revenue has grown by 133.05% in the past year. This is a very strong growth!
Measured over the past years, NXGL shows a very strong growth in Revenue. The Revenue has been growing by 64.56% on average per year.
EPS 1Y (TTM)32.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.71%
Revenue 1Y (TTM)133.05%
Revenue growth 3Y77.64%
Revenue growth 5Y64.56%
Sales Q2Q%100.28%

3.2 Future

The Earnings Per Share is expected to grow by 33.27% on average over the next years. This is a very strong growth
NXGL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 38.07% yearly.
EPS Next Y42.88%
EPS Next 2Y52.53%
EPS Next 3Y44.54%
EPS Next 5Y33.27%
Revenue Next Year44.56%
Revenue Next 2Y46.25%
Revenue Next 3Y44.56%
Revenue Next 5Y38.07%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NXGL Yearly Revenue VS EstimatesNXGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M
NXGL Yearly EPS VS EstimatesNXGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.5 -0.5 1 1.5

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NXGL. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 14.09 indicates a correct valuation of NXGL.
NXGL's Price/Forward Earnings ratio is rather cheap when compared to the industry. NXGL is cheaper than 86.84% of the companies in the same industry.
NXGL's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.48.
Industry RankSector Rank
PE N/A
Fwd PE 14.09
NXGL Price Earnings VS Forward Price EarningsNXGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NXGL Per share dataNXGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

NXGL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as NXGL's earnings are expected to grow with 44.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.53%
EPS Next 3Y44.54%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NXGL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEXGEL INC

NASDAQ:NXGL (9/3/2025, 8:00:02 PM)

2.3

-0.05 (-2.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)N/A N/A
Inst Owners9.02%
Inst Owner Change11.06%
Ins Owners14.72%
Ins Owner Change-2.34%
Market Cap18.56M
Analysts82.86
Price Target6.12 (166.09%)
Short Float %0.52%
Short Ratio0.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.14%
Min EPS beat(2)-26.05%
Max EPS beat(2)11.76%
EPS beat(4)1
Avg EPS beat(4)-7.49%
Min EPS beat(4)-26.05%
Max EPS beat(4)11.76%
EPS beat(8)4
Avg EPS beat(8)-9.14%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-3.64%
Min Revenue beat(2)-8.21%
Max Revenue beat(2)0.94%
Revenue beat(4)2
Avg Revenue beat(4)-1.6%
Min Revenue beat(4)-8.21%
Max Revenue beat(4)1.24%
Revenue beat(8)4
Avg Revenue beat(8)-3.31%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-700%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-100%
EPS NY rev (3m)-366.67%
Revenue NQ rev (1m)-8.3%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-3.77%
Revenue NY rev (3m)-3.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 14.09
P/S 1.59
P/FCF N/A
P/OCF N/A
P/B 3.97
P/tB 6.63
EV/EBITDA N/A
EPS(TTM)-0.4
EYN/A
EPS(NY)0.16
Fwd EY7.1%
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS1.45
BVpS0.58
TBVpS0.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.07%
ROE -62.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 38.62%
FCFM N/A
ROA(3y)-35.81%
ROA(5y)-46.56%
ROE(3y)-62.13%
ROE(5y)-690.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y266%
GM growth 5YN/A
F-Score6
Asset Turnover1.2
Health
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.73%
Cap/Sales 0.87%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.74
Quick Ratio 0.98
Altman-Z -0.15
F-Score6
WACC8.63%
ROIC/WACCN/A
Cap/Depr(3y)166.83%
Cap/Depr(5y)273.19%
Cap/Sales(3y)9%
Cap/Sales(5y)18.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.71%
EPS Next Y42.88%
EPS Next 2Y52.53%
EPS Next 3Y44.54%
EPS Next 5Y33.27%
Revenue 1Y (TTM)133.05%
Revenue growth 3Y77.64%
Revenue growth 5Y64.56%
Sales Q2Q%100.28%
Revenue Next Year44.56%
Revenue Next 2Y46.25%
Revenue Next 3Y44.56%
Revenue Next 5Y38.07%
EBIT growth 1Y18.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year88.89%
EBIT Next 3Y61.03%
EBIT Next 5Y36.32%
FCF growth 1Y20.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.73%
OCF growth 3YN/A
OCF growth 5YN/A